Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05WQT
|
|||
Former ID |
DIB008520
|
|||
Drug Name |
Flanvotumab
|
|||
Synonyms |
IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | |
Company |
Eli lilly
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Melanoma antigen gp75 (TYRP1) | Target Info | . | [2] |
BioCyc | Eumelanin biosynthesis | |||
KEGG Pathway | Tyrosine metabolism | |||
Metabolic pathways | ||||
Melanogenesis | ||||
Pathwhiz Pathway | Degradation of Superoxides | |||
Pathway Interaction Database | Direct p53 effectors |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01137006) An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma. U.S. National Institutes of Health. | |||
REF 2 | National Cancer Institute Drug Dictionary (drug id 675217). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.